Transcriptomics

Dataset Information

0

SGLT2 inhibitors and zebrafish


ABSTRACT: The CANVAS program revealed that the SGLT2 inhibitor canagliflozin increases the risk for lower-limb (minor) amputations in type 2 diabetics about a two-fold. On the contrary, the large RCTs with empagliflozin and dapagliflozin did not demonstrate a similar observation. Thus, a question arises whether the increased risk for minor amputations is associated only with canagliflozin or whether it is a class effect of SGLT2 inhibitors. Vascular disorders including defective angiogenesis are among the leading causes of lower-limb amputations. Therefore, here we examined the effects of empagliflozin, dapagliflozin, and canagliflozin on angiogenesis using zebrafish embryos and HUVECs.

ORGANISM(S): Danio rerio

PROVIDER: GSE191046 | GEO | 2022/12/31

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2023-11-14 | GSE247062 | GEO
2023-04-04 | GSE228909 | GEO
2022-10-19 | GSE200322 | GEO
2023-11-14 | GSE247061 | GEO
2023-04-04 | GSE228910 | GEO
2023-09-10 | GSE239688 | GEO
| PRJNA789531 | ENA
| PRJNA1000568 | ENA
2022-12-12 | GSE200598 | GEO
2024-11-14 | GSE279174 | GEO